Takeda to Sell Consumer Unit to Blackstone for $2.3 Billion
- Blackstone to invest 50 billion yen into unit with IPO plan
- Sale is part of Takeda’s goal of $10 billion in asset disposal
This article is for subscribers only.
Takeda Pharmaceutical Co. agreed to sell its Japanese consumer health-care business for 242 billion yen ($2.3 billion) to Blackstone Group Inc., which plans to take the over-the-counter medication unit public in about five years.
For the drugmaker, the sale represents another piece of its plan to dispose $10 billion in assets after its $62 billion mega-acquisition of Shire Plc last year.